Introduction
Circadian rhythms are regulated by an endogenous circadian pacemaker that resides in the suprachiasmatic nuclei (SCN) in mammals. This pacemaker is the Master Body Clock that regulates the circadian rhythms of biological processes including the secretion of hormones such as melatonin and cortisol, sleep-wake cycles, alertness and performance patterns, metabolism and cardiovascular processes (Lockley et al., , 2008 . In human, the endogenous rhythm of the SCN is typically slightly longer than 24 h and therefore must be entrained (synchronized) to the 24-h day. The strongest zeitgeber responsible for entrainment is the daily lightedark cycle, detected primarily by the intrinsically photosensitive ganglion cells of the retina (Czeisler and Gooley, 2007; Ramsey et al., 2013) .
Disruptions in a person's circadian rhythms have been recognized to play a significant role in the etiology of a number of serious and chronic disorders, including obesity (Karlsson et al., 2001) , diabetes (Morikawa et al, 2005) , breast cancer (Davis et al., 2001; Schernhammer et al, 2001 ), colorectal cancer (Schernhammer et al, 2003) , cardiovascular diseases (Vyas et al, 2012; Ruger and Scheer, 2009; Knutsson, 2003) , depression (Boyce and Barriball, 2010; Monteleone and Maj, 2008; Turek, 2007) , and circadianrhythm sleep-wake disorders (Sack et al, 2007) like Non-24-Hour Sleep-Wake Disorder (Non-24) Skene et al., 1999) . Non-24 is a serious, debilitating, chronic disorder that occurs when individuals are unable to synchronize their endogenous circadian clock to the 24-h light-dark cycle (American Psychiatric Association, 2013; American Academy of Sleep Medicine, 2005) . The majority of reported cases of Non-24 occur in blind patients with no conscious perception of light  Uchiyama and Lockley, 2009 ). The growing understanding of the importance of circadian regulation in these complex disorders is expected to spawn the development of specifically designed circadian regulators that can address the underlying circadian component of these conditions. Abbreviations: AMP, Adenosine monophosphate; BSA, Bovine serum albumin; cAMP, Cyclic AMP; DMRA, Dual Melatonin Receptor Agonist; EC 50 , 50% of the maximal effect; EDTA, Ethylenediaminetetraacetic acid; E max , Maximal effect; GABA, Gamma-aminobutyric acid; HEPES, 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; IBMX, 3-isobutyl-1-methylxanthine; IC 50 , Concentration producing 50% of the maximal effect; K i , Dissociation constant for the inhibitor; NMDA, N-methyl-D-aspartate; Non-24, Non-24-Hour Sleep-Wake Disorder; PKC, Protein kinase C; PMSF, phenylmethylsulfonyl fluoride; SCN, Suprachiasmatic nuclei; TRIS, Tris(hydroxymethyl)aminomethane; 4-P-PDOT, Cis-4-Phenyl-2-propionamidotetralin(.Tasimelteon is a novel structurally unique molecular entity, chemically designated as (1R, 2R)-N-[2-(2,3-dihydrobenzofuran-4-yl)cyclopropylmethyl]propanamide, containing two chiral centers that was developed for the treatment of Non-24. Its molecular formula is C 15 H 19 NO 2 , and the molecular weight is 245.32. Tasimelteon differs structurally from melatonin and drugs with known melatonin agonist activity, in particular by its distinct aromatic group and linker (Fig. 1) . Tasimelteon bears also no structural relationship to any other approved active substance.
Tasimelteon was specifically developed to treat the underlying circadian basis of Non-24, and has undergone rigorous safety evaluation (Swick et al., 2014; Sliman et al., 2014; Quera-Salva et al., 2014; Lockley et al., unpublished results) . Non-24 is a circadian rhythm disorder, which primarily affects totally blind individuals, characterized by the inability to entrain the master body clock to the 24-h lightedark cycle (American Psychiatric Association, 2013; American Academy of Sleep Medicine, 2005) . It is estimated that seventy percent of blind individuals with no light perception have Non-24 (Sack and Lewy, 2001) . Patients with Non-24 have prolonged periods of misalignment of circadian rhythms, including the timing of melatonin and cortisol secretion and the sleep-wake cycle, which are associated with significant impairments in social and occupational functioning, and marked subjective distress (American Psychiatric Association, 2013) .
Studies reported here investigated the binding characteristics of tasimelteon for a wide range of receptors and other pharmacological targets, in particular the G protein-coupled melatonin MT 1 and MT 2 receptors, which are expressed in the central nervous system and in peripheral tissues (Dubocovich and Markowska, 2005) . Results point to the unique receptor binding profile of tasimelteon, which acts as a selective and potent DMRA with greater affinity for the MT 2 receptor than for the MT 1 receptor, and no appreciable affinity for more than 160 other pharmacologically relevant receptors and enzymes, including the gammaaminobutyric acid (GABA) receptor complex and receptors that bind neuropeptides, cytokines, serotonin, noradrenaline, acetylcholine, and opiates.
Materials and methods
The specific affinity of tasimelteon for the MT 1 and MT 2 receptors was evaluated in two independent experiments using human recombinant receptors and radioligand binding assays. The selectivity of the receptor binding was further evaluated by determining the affinity for more than 160 other receptors and several enzymes. Furthermore, inhibition of forskolin-stimulated cyclic adenosine monophosphate (cyclic AMP or cAMP) accumulation was conducted in NIH-3T3 cells stably expressing the human MT 1 and MT 2 receptors.
Binding assays at the MT 1 and MT 2 receptors
In a first experiment, two lines of NIH-3T3 cells were used; one cell line stably expressed the human MT 1 receptor while the second cell line stably expressed the human MT 2 receptor. Cells were maintained and passaged as attached monolayers in Dulbecco's Modified Eagle Medium containing D-glucose, 10 mM HEPES, 10% heat inactivated calf serum and 500 mg/mL geneticin. Cultures were incubated in vented tissue culture flasks at 37 C in a humidified atmosphere containing 5% CO 2 . Cells were harvested and frozen as pellets at À80 C. Membrane homogenates were prepared in assay buffer (50 mM TRIS containing 12.5 mM MgCl 2 and 2 mM EDTA, pH 7.4 at 37 C with HCl) fortified with 10 mg/mL aprotinin and leupeptin and 100 mM PMSF, using a Dounce homogenizer. The resulting homogenate was centrifuged (45,000 Â g, 10 min, 4 C) and the pellet was resuspended in fortified assay buffer at a ratio of 0.25 mL per original flask of cells and frozen in aliquots at À80 C until use. Binding assays were performed in duplicate in a total volume of 0.2 mL containing 0.16 mL membrane homogenate diluted appropriately, 0.02 mL 2-[
125 I]iodomelatonin (0.1 or 0.2 nM final concentration for MT 1 or MT 2 , respectively) and 0.02 mL assay buffer, melatonin or tasimelteon. Nine concentrations of tasimelteon (0.001 nM, 0.01 nM, 0.03 nM, 0.1 nM, 0.3 nM, 1 nM, 3 nM, 10 nM, and 100 nM) and 5 concentrations of melatonin (0.01 nM, 0.1 nM, 1 nM, 10 nM, and 100 nM) were used for each MT 1 or MT 2 binding assay. Non-specific binding was determined in the presence of 10 mM melatonin. Assays were initiated by the addition of membrane homogenates and incubated for 60 min at 37 C. Assays were terminated by rapid filtration onto Whatman GF/B filters with a Brandel cell harvester. Filters were washed 3 times with 4 mL ice-cold 20 mM TRIS containing 2 mM MgCl 2 , pH 7.4 at 25 C. Bound radioactivity was quantitated by gamma emission spectrometry. Data were analyzed by a 4-parameter logistic, non-linear least squares regression (DeLean et al., 1978) to yield IC 50 values (concentration producing 50% of the maximal effect), which were converted to dissociation constant for the inhibitor (K i ) values (Cheng and Prusoff, 1973) . In a second experiment, two lines of CHOeK1 cells were used; one cell line expressed the human MT 1 receptor while the other expressed the human MT 2 receptor. Radioligand binding assays were performed with 0.05 nM 2-[
125 I]iodomelatonin used as the ligand, with a 4 h incubation at 25 C in 25 mM HEPES, pH 7.4, 5 mM MgCl, 1 mM CaCl, 0.1% BSA. 6-Chloromelatonin (1 mM) was used as nonspecific ligand. The reference compounds used for the MT 1 or MT 2 binding assays were melatonin and 4-P-PDOT, respectively; 4-P-PDOT was used in this second experiment because it was shown to have substantially higher affinity for the MT 2 receptor than for the MT 1 receptor (Browning et al., 2000) . 
Cyclic adenosine monophosphate assays
Cyclic AMP assays were performed using NIH-3T3 cells stably expressing human MT 1 or MT 2 receptors. Cells were incubated in culture media containing 1 mM IBMX and 10 mM forskolin for 10 min at 37 C in the presence of increasing concentrations (1 pMe10 mM) of melatonin or tasimelteon. Assays were terminated by the addition of 0.1 N HCl. Following centrifugation, supernatants were collected and stored at À20 C until assayed. Cyclic AMP levels were measured by radioimmunoassay (Amersham). Radioactivity was quantitated by gamma emission spectrometry. Three separate experiments were performed in duplicate. Data were analyzed by a 4-parameter logistic, non-linear least squares regression (DeLean et al., 1978) to yield concentration producing 50% of the maximal effect (EC 50 ) and maximal effect (E max ) values.
Extended binding profile
Standard radioligand binding and enzyme inhibition assays were performed on receptors, binding sites or enzyme systems obtained from various sources, including human, rat, mouse, guinea pig, rabbit, hamster, and bovine tissues (see Supplemental Information), using the ProfilingScreen and DiscoveryScreen panels (Panlabs) which consisted of 56 radioligand binding assays and 7 enzyme assays, respectively, and the SpectrumScreen panel (MDS Pharma Services) that included 170 pharmacological relevant targets (see Supplemental Information). In addition, the GABA A benzodiazepine and GABA B binding sites were also tested independently (Panlabs biochemical pharmacology assays). Tasimelteon was used at a concentration of 10 mM except for 2 enzyme assays (Protein kinases C: PKCa and PKCb) where it was used at 100 mM, and for the melatonin receptors in the SpectrumScreen panel where 4 concentrations (10 nM, 0.1 mM, 1 mM and 10 mM) were tested. A response was considered significant if there was !50% inhibition or stimulation for the assays.
The affinity of tasimelteon (10 mM) for the human hypocretin (orexin) receptor 1 expressed in transfected CHO cells, and for the human hypocretin (orexin) receptor 2 expressed in transfected HEK-293 cells, was determined in radioligand binding assays (Eurofins Cerep SA, Celle l'Evescault, France). expressed in NIH-3T3 cells. In this experiment, tasimelteon displayed comparable potency to melatonin at the MT 1 receptor and stronger potency than melatonin (P < 0.05) at the MT 2 receptor (Fig. 2) . Non-linear regression analysis of the data for the MT 1 receptor yielded pK i values (±standard error of the mean) of 9.39 ± 0.02 (K i ¼ 0.41 nM) for melatonin and pK i ¼ 9.45 ± 0.04 (K i ¼ 0.35 nM) for tasimelteon (Table 1) ; for the MT 2 receptor values were pK i ¼ 9.57 ± 0.03 (K i ¼ 0.27 nM) for melatonin and pK i ¼ 9.77 ± 0.07 (K i ¼ 0.17 nM) for tasimelteon ( Table 1) . Analysis of similar binding assays performed with CHOeK1 cells confirmed a higher affinity of tasimelteon for the MT 2 receptor, with K i ¼ 0.304 nM and K i ¼ 0.0692 ± 0.007 nM for MT 1 and MT 2 respectively (Fig. 3, Table 1 ). In CHOeK1 cells, positive controls melatonin and 4-P-PDOT had K i values of 0.246 ± 0.039 nM and 0.273 ± 0.023 nM for MT 1 and MT 2 , respectively. Binding kinetics were best fit to a one-site binding model, suggesting a single receptor interaction. Taken together, results indicate that tasimelteon is a DMRA with 2.1e4.4 times greater affinity for the MT 2 receptor than for the MT 1 receptor (Table 1 ). For melatonin, affinity for the MT 2 receptor was 1.5 fold higher than for the MT 1 receptor in NIH-3T3 cells.
Results

Tasimelteon potently inhibits 2-[
Tasimelteon was shown to induce a potent, concentrationdependent inhibition of forskolin-stimulated cAMP accumulation in NIH-3T3 cells stably expressing human MT 1 (pEC 50 ¼ 9.1 ± 0.1, EC 50 ¼ 0.74 nM, and E max ¼ 59 ± 1%) or expressing human MT 2 (pEC 50 ¼ 9.0 ± 0.1, EC 50 ¼ 0.1 nM, and E max ¼ 60 ± 3%) receptors (Fig. 4) .
No significant responses (!50% inhibition or stimulation) were observed in any radioligand receptor binding assay (Table 2 ) and enzyme assays (Table 3) , except for both melatonin receptors MT 1 and MT 2 assays for which approximately 100% inhibition was achieved at 10 nM. Because of overlaps between the ProfilingScreen and DiscoveryScreen panels (Panlabs) and the SpectrumScreen panel (MDS Pharma Services) forty two receptors were tested twice, in some cases with a different assay (i.e. different ligand or different source of receptor); results were consistent in all cases, showing no significant binding affinity for these receptors.
Discussion and conclusions
Tasimelteon was shown to have full agonist activity at both melatonin receptors, with greater affinity for the MT 2 receptor as compared to the MT 1 receptor in 2 independent experiments where the human melatonin receptors were expressed in different cell lines. The K i values of tasimelteon showed numerical differences between cell lines for each melatonin receptor, and between melatonin receptors for each cell line, but remained within the same order of magnitude (Table 1 ). Such differences are not unexpected for studies with different experimental conditions and may be due to variations in cellular environment (Nelson and Challiss, 2007) , receptor reserve (Zhu, 1993) or receptor expression and coupling (Luttrell, 2006) , which can affect the K i estimation ( Van et al., 1997) . Results were consistent across experiments in demonstrating the binding affinity of tasimelteon for both melatonin receptors, and in indicating a higher MT 1 /MT 2 K i ratio.
MT 1 and MT 2 melatonin receptors are present in several areas of the central nervous system, including the SCN, the pars tuberalis, and the retina, as well as in peripheral tissues such as kidney, pancreas, testes, adrenal cortex, and the immune and cardiovascular systems (Dubocovich and Markowska, 2005) . The MT 1 receptor has been implicated in the modulation of neuronal firing (Liu et al, 1997; Jin et al, 2003) , cardiac vessel constriction (Krause et al., 1995) , reproductive functions (Johnston et al., 2003a; Johnston et al, 2003b) , and metabolic functions (Peschke, 2008; Kemp et al., 2002) . The MT 2 receptor is believed to mediate circadian rhythm phase-shifting (Liu et al, 1997; Dubocovich et al., 1998 Dubocovich et al., , 2005 Hunt et al., 2001) , and was recently implicated in the regulation of sleep (Ochoa-Sanchez et al, 2011) .
While the binding affinity of tasimelteon for the melatonin receptors has not been determined in vivo, the clinical effects of tasimelteon are consistent with the results of the in vitro experiments. Tasimelteon has demonstrated the ability to phase-advance the sleep-wake cycle and improve nighttime sleep and daytime sleep (Lockley et al., 2013a (Lockley et al., , 2013b Rajaratnam et al, 2009; Torres et al., 2014) . Tasimelteon has also demonstrated its ability to phase-advance and entrain the SCN as measured by the circadian rhythm profile of the hormones melatonin and cortisol (Lockley et al, 2013a (Lockley et al, , 2013b Rajaratnam et al, 2009) .
Tasimelteon had no significant interaction with any other commonly screened receptors or enzyme binding sites tested, including a wide array of receptors of neurotransmitter systems such as dopamine, norepinephrine, serotonin, GABA, acetylcholine, opioid, N-methyl-D-aspartate (NMDA), hypocretin (orexin), and cannabinoid; this finding supports the observation that tasimelteon did not produce signs or symptoms indicative of abuse potential in animal or clinical studies and did not produce withdrawal symptoms after discontinuation of chronic administration (Hetlioz ® prescribing information: https://www.hetlioz.com, accessed Aug 27, 2014).
Tasimelteon's receptor binding profile is distinct from that of two other molecules known to bind both melatonin receptors, ramelteon and agomelatine; ramelteon has 8 times lower affinity for the MT 2 receptor than for the MT 1 receptor (Kato et al, 2005) , and agomelatine, a non-specific melatonin agonist, has a 4.4 times lower affinity for the MT 2 receptor than for the MT 1 receptor and binds also to several serotonin 5-HT 2 receptors (Millan et al, 2003; Bourin et al., 2004) .
The selective and unique receptor binding profile of tasimelteon supports its pharmacological properties as a circadian regulator including in particular its ability to phase advance and entrain circadian rhythms as demonstrated in healthy volunteers (Rajaratnam et al, 2009 ) and in patients with Non-24 (Lockley et al, 2013a) , which leads to improvement in sleep-wake measures and global function in patients affected with Non-24 (Lockley et al, 2013a (Lockley et al, , 2013b Torres et al., 2014) . 
